BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21263218)

  • 1. Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
    Feng J; Fang H; Wang X; Jia Y; Zhang L; Jiao J; Zhang J; Gu L; Xu W
    Cancer Biol Ther; 2011 Mar; 11(5):477-89. PubMed ID: 21263218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
    Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
    Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
    Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
    Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors.
    Gediya P; Vyas VK; Carafa V; Sitwala N; Della Torre L; Poziello A; Kurohara T; Suzuki T; Sanna V; Raguraman V; Suthindhiran K; Ghosh D; Bhatia D; Altucci L; Ghate MD
    Bioorg Chem; 2021 May; 110():104801. PubMed ID: 33756235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
    Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring novel capping framework: high substituent pyridine-hydroxamic acid derivatives as potential antiproliferative agents.
    Hernández-Borja F; Mercado-Sánchez I; Alcaraz Y; García-Revilla MA; Villegas Gómez C; Ordaz-Rosado D; Santos-Martínez N; García-Becerra R; Vazquez MA
    Daru; 2021 Dec; 29(2):291-310. PubMed ID: 34297326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
    Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
    Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
    Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
    Wang L; Chen G; Chen K; Ren Y; Li H; Jiang X; Jia L; Fu S; Li Y; Liu X; Wang S; Yang J; Wu C
    Oncotarget; 2015; 6(12):9740-55. PubMed ID: 25762635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
    Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
    Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
    Hirata Y; Hirata M; Kawaratani Y; Shibano M; Taniguchi M; Yasuda M; Ohmomo Y; Nagaoka Y; Baba K; Uesato S
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1926-30. PubMed ID: 22321215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
    Srivastava RK; Kurzrock R; Shankar S
    Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21
    Tseng TH; Chien MH; Lin WL; Wen YC; Chow JM; Chen CK; Kuo TC; Lee WJ
    Environ Toxicol; 2017 Feb; 32(2):434-444. PubMed ID: 26872304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.